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Abstract

Author Manuscript

Active metabolic pathways in three-dimensional cancer-cell cultures are potential
chemotherapeutic targets that would be effective throughout tumors. Chaotic vasculature creates
cellular regions in tumors with distinct metabolic behavior that are only present in aggregate cell
masses. To quantify cancer cell metabolism, transformed mouse fibroblasts were grown as
spheroids and fed isotopically labeled culture medium. Metabolite uptake and production rates
were measured as functions of time. Gas chromatography - mass spectrometry was used quantify
the extent of labeling on amino acids present in cytoplasmic extracts. The labeling pattern
identified several active and inactive metabolic pathways: glutaminolysis was found to be active,
and malic enzyme and gluconeogenesis were inactive. Transformed cells in spheroids were also
found to actively synthesize serine, cysteine, alanine, aspartate, glutamate, and proline; and not
synthesize glutamine. The activities of these pathways suggest that cancer cells consume
glutamine for biosynthesis and not to provide cellular energy. Determining active metabolic
pathways indicates how cells direct carbon flow and may lead to the discovery of novel molecular
targets for anti-cancer therapy.
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Introduction

Author Manuscript

Understanding the metabolism of cancer cells in three-dimensional tissue could play a key
role in the development of targeted cancer therapeutics1–2. Identifying active metabolic
pathways defines the behavior of cancer cells grown under physiological conditions and can
identify enzymatic targets for therapy. Several metabolic pathways have previously been
proposed as targets for anti-cancer agents3–6. Inhibitors for the key enzymes in these
pathways have been shown to reduce cancer cell growth and are promising therapeutics6–11.
Multicellular spheroids are circular clusters of cells grown suspended in culture
medium2, 12–13. Spheroids mimic the distribution of cell populations in tumors and create
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more realistic cell-cell interactions than monolayer cultures. Similar to tumors in vivo, most
cells in spheroids touch neighboring cells on all sides. In addition, the chaotic vasculature in
tumors14–15 creates distinct populations of cells with unique physiologies based on their
distance to the nutrient supply12. The concentric layers of cell in spheroids replicate the
distinct metabolic microenvironments that are arranged around blood vessels in tumors12.
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The intracellular metabolism of cancer cells grown as spheroids can be rapidly investigated
using stable 13C labeling and gas chromatography mass spectrometry (GC-MS). In a typical
isotope experiment, labeled substrates are introduced into cell culture systems and
intracellular metabolite labeling is measured. Two common isotope measurement techniques
are mass spectrometry (MS) and nuclear magnetic resonance (NMR) spectroscopy1–2, 16–17.
The major advantage of mass spectrometry is that it requires considerably less cellular
material. Comparatively, NMR has the advantage of being able to identify specific labeling
positions1–2. The smaller sample sizes required for GC-MS enables experiments to be run
more rapidly and reduces the use of expensive labeled substrates. Increased sensitivity also
considerably reduces required culture sizes, reduces mammalian culture apparatus, and
increases culture uniformity. Previously, isotopic labeling and GC-MS has been used to
measure metabolism in numerous mammalian systems, including hepatic cells18–20, cardiac
cells21, and glial cells22.
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Here we describe the use of 13C labeling and GC-MS analysis to investigate the metabolism
of transformed fibroblasts cells grown as spheroids. Both small and large spheroids were
grown to identify the metabolic differences between proliferating and quiescent cells. Basic
metabolic behavior was determined by measuring the rates of metabolite uptake and
production. The labeling patterns of cytosolic amino acids were determined and used to
identify active and inactive metabolic pathways. Metabolic analysis of cancer cells in
physiologically relevant, three-dimensional culture is important because it will help identify
critical metabolic pathways and future targets for cancer therapeutics.

METHODS
Cell and Spheroid Culture

Author Manuscript

Mouse embryonic ras-transformed fibroblasts derived from embryonic stem cells were a
kind gift from Dr. R. Johnson (University of California, San Diego). This artificially
transformed cell line does not directly mimic a specific human tumor, but has been shown to
form tumors in mice23. Cells were grown in high glucose Dulbecco Modified Eagle Medium
(DMEM; 4.5 g/L glucose) containing 20mM HEPES buffer (pH 7.4) supplemented with
10% fetal bovine serum. All reagents were obtained from Sigma-Aldrich (St. Louis, MO)
unless otherwise noted. Cultures were maintained at 37°C with 5% CO2 in a humidified
incubator. Spheroids were formed by inoculating a single-cell suspension into flasks coated
with poly(2-hydroxyethyl methacrylate) at a density of 106 cells/mL. The methacrylate
coating prevented cell adhesion to the flask surface. Average spheroid size was dependent on
time in culture as described previously2.
Spheroid size was determined by acquiring microscope images of spheroids suspended in 2–
5 ml drops of culture medium, removed from well-mixed T-flasks. Microscopy was
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performed with an Olympus IX71 inverted microscope equipped with a 10× Plan-APO
fluorescence objective and IPLab software (Scanalytics, Fairfax, VA). Diameters were
measured by manually fitting ellipses to the spheroid boundaries and measuring the length
of the major axis. The number of cells in spheroid cultures was determined by counting the
number of cells in 1ml of medium removed from well-mixed T-flasks. Samples were
centrifuged and the medium was removed. After washing with 1ml PBS, spheroids were
treated with trypsin-EDTA for 10 minutes and dissociated by repeated pipetting. Complete
media and trypan blue were added and the number of cells was manually counted using a
hemocytometer.
Experimental Protocol

Author Manuscript
Author Manuscript

Small and large spheroid cultures were both derived from the same initial spheroid cultures.
After seven days of growth, two culture flasks were combined and 25% of the volume was
separated. This smaller fraction was allowed to continue growing for 12 additional days to
form large spheroids. The remaining 75% of the culture volume containing small spheroids
was immediately analyzed. Small, 7-day-old and large, 19-day-old spheroids were analyzed
identically. Culture media was replaced with isotopically labeled medium, prepared by
supplementing DME base medium with 4.5 g/L 1-13C glucose (Cambridge Isotope
Laboratories, Andover, MA) and standard concentrations of L-glutamine (0.584 g/L), phenol
red (0.0159 g/L), sodium pyruvate (0.11 g/L) and sodium bicarbonate (3.7g/L). Media
samples were taken every 4 hours and the concentrations of glucose, lactate, glutamate and
glutamine were measured with a biochemistry analyzer (YSI, Yellow Springs, OH). After 24
hours, the spheroid concentration, average spheroid diameter, and overall cell concentration
were measured. The cells in the cultures were then centrifuged at room temperature,
resuspended in water and homogenized with a hand-held homogenizer (Ultra-TurraxT25,
Rose Scientific Ltd., Edmonton, Alberta) for 3 minutes. The time from centrifugation to
homogenization was kept beneath 10 minutes to minimize isotopic rearrangement in
intracellular metabolite pools. Water was removed from cell extracts by lyophilization. Each
experiment was repeated twice and reported values are averages of the two runs.
Extracellular fluxes were calculated by determining the slope of the metabolite
concentration profile, multiplying by the volume, and dividing by the number of cells in the
culture1–2.
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Samples were derivatized and analyzed by GC-MS using procedures similar to those
describe previously16–17, 24. Equal parts N,N-dimethylformamide (DMF) and N-methyl-N(tert-butyldimethyl-silyl) trifluoroacetamide (MTBSTFA) were added to the dry lyophilized
extracts. Between 30 and 40 µL of each solvent was used depending on the volume of the
extract. The mixtures were stirred and heated at 70° C for 30 minutes. This reaction added a
tert-butyldimethylsilyl (tBDMS) group to the carboxyl and amine ends of each amino acid25
(Figure 1A). Analysis was performed by injecting 1.5 µL of derivatized sample into a
quadropole GC-MS system (HP 5890 GC and 5894 MS). A single injection was made per
sample. The GC was programmed to initiate a thermal ramp starting at 140°C and increase
by 3°C per minute until reaching 250°C. The mass spectrometer operated in electron impact
ionization mode and fragments were detected with a quadrupole analyzer.
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The mass spectra for each amino acid were corrected for the presence of natural isotopes.
The isotope distribution observed for each amino acid was caused by two mechanisms: 1)
incorporation of 13C atoms from labeled glucose in the media and 2) the presence of natural
isotopes. To determine the extent of label incorporation, the distribution of natural isotopes
had to be subtracted from the observed distribution. This subtraction is possible because
natural isotope distribution is constant and predictable.
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After ionization in the spectrometer, many molecular fragments are produced for each
derivatized amino acid. Two of major ionization fragments are the R-tbutyl and the RCOOtBDMS fragments (Figure 1A). As examples, these two fragments of glutamate have
molecular weights of 330 and 432. The whole derivatized glutamate molecule contains three
tBDMS groups and weighs 489 g/mol. Because the tBDMS group is relatively large (Figure
1A), the probability of a fragment containing a naturally occurring, heavy isotope of carbon,
silicon, oxygen or hydrogen is quite large. Specifically, the chance of the 432 fragment of
glutamate containing exactly one heavy atom is 23.3% (m1 in figure 1B). Figure 1B shows
the entire predicted mass distribution for unlabeled glutamate fragment 432. During
analysis, only the R-tbutyl fragment of each amino acid was used because it was the most
predominant. This fragment also provided the most information, because it contained all of
the original carbon atoms.
To determine the extent of labeling four vectors were defined: the measured mass
distribution for each amino acid (D), the mass distribution of each amino acid fragment due
to natural isotope abundance (m), the extent of labeling from isotopically labeled glucose
(M), and a vector of residual errors (E). For example, the natural isotopic content of the 432
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) is shown in Figure 1B. The following equation was used
R-tbutyl glutamate fragment (
to account for the distribution of natural isotopes on each labeled molecule:

(1)

Higher order terms were neglected, because peaks greater than M+4 were not detected. The
value of the M vector was determined iteratively. An initial value was guessed and
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subsequently adjusted using a non-linear solver until the sum of least squared errors
was minimized. Statistical significance was determined by averaging the labeling from four
experiments and calculating the probability that the labeling fraction was zero.
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Results and Discussion
Spheroid Size and Extracellular Metabolism
Small and large spheroids contained considerably different populations of cells and had
measurably different extracellular metabolism. The average sizes of small and large
spheroids were 425 and 755 µm, respectively, and large spheroids contained almost 50%
more cells per spheroid (Figure 2). In previous experiments with the same cell line the
thicknesses of the proliferating and quiescent regions were determined to be 75 and 40 µm12.
Based on these measurements, the ratio of quiescent to proliferating cells in small and large
spheroids was 24% and 37%, and large spheroids had 54% more quiescent cells (Figure 2A).

Author Manuscript

Rates of metabolite uptake and production were determined from extracellular concentration
profiles (Figure 2B and C). By convention1–2, the absolute value of all fluxes are reported,
i.e. glucose and glutamine were consumed and lactate and glutamate were produced (Figure
2D). Large spheroids had higher rates of glucose consumption and lactate production, and
the rates of glutamate production and glutamine consumption were similar (Figure 2D). The
differences in the extracellular fluxes of glucose and lactate indicate that larger spheroids
have higher rates of glycolysis. However, the ratio of lactate produced per glucose molecule
drops from 1.93 to 1.55 as spheroid size increases. There are several possibilities that could
explain the decrease in this ratio: 1) increased aerobic metabolism facilitated by available
oxygen and reuptake of lactate, or 2) diversion of more glucose carbons into the nonoxidative reactions of the pentose phosphate pathway to synthesize ribose.
Amino Acid Labeling in Spheroids
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In the homogenized and derivatized cell extracts, 16 amino acids were detected at distinct
elution times (Figure 3A) and mass spectra were identified with multiple fragmentation
patterns (Figure 3B). As a representative example, the predominant glutamtate peaks at 432
and 330 (Figure 3B) are the R-tbutyl and the R-COOtBDMS fragments17, 25. A mass
distribution was observed for each fragment (Figure 3C&D). In most fragments M, M+1, M
+2, M+3, M+4 and M+5 peaks were observed. The extent of labeling was determined by
accounting for natural isotope abundance. For example, in the mass distribution for
glutamate 432 (Figure 3E) the 433 peak contains two species: 1) singly labeled glutamate
(M+1, white bar) and 2) unlabeled glutamate (M+0) with one additional mass unit due to
naturally abundant isotopes (black bar). For all amino acids, the extent of labeling was
identical for both the R-tbutyl and R-COOtBDMS fragments.
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The amino acid isotopomer distribution was almost identical for small and large spheroids
(Figures 4 and 5). For both the essential (Figure 4) and non-essential (Figure 5) amino acids,
no significant difference in isotope labeling was observed. This suggests that despite
differences in spheroid size, quiescent cell content, and extracellular metabolism (Figure 2),
intracellular metabolism was similar for both spheroid sizes. No labeling was observed on
any essential amino acids (Figure 4), because, as expected, mammalian cells cannot
synthesize these. The apparent labeling of lysine was not significantly greater than zero
(P=1.3) and was an experimental aberration. These results with essential amino acids
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provide a check of the method used to subtract naturally abundant isotopes: the observed
mass distributions matched that expected due to natural abundance.
Labeling of Non-Essential Amino Acids
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Labeling patterns observed on nonessential amino acids (Figure 5) suggest which
intracellular pathways were active in cells grown as spheroids (Figure 6, Table 1). The
metabolic map includes the pathways of primary metabolism, including glycolysis, the
tricarboxylic acid (TCA) cycle, transport of molecules in and out of mitochondria, and the
synthesis of non-essential amino acids (Figure 6). These results describe the intracellular
metabolism of transformed cells under cell culture conditions; in vivo metabolism will vary
depending on many variables including time, metabolic microenvironment and tumor cite. In
culture, at least one other cell line, MCF7 breast cancer cells, has been shown to have similar
patterns of pathway activity1. For analysis, amino acids were grouped into those synthesized
from glycolysis metabolites (Figure 5A), and those synthesized from TCA-cycle metabolites
(Figure 5B).
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The presence of M+1 labeling on serine (P<0.01) and cysteine (P<0.05; Figure 5A) indicates
that serine synthesis (pathways a in Figure 6) and cysteine synthesis (pathways b) are both
active. Serine is synthesized from 3-phosphoglycerate by a pathway that includes the
enzymes 3-phosphoglycerate dehydrogenase, and phosphoserine phosphatase. The carbon
backbone of cysteine is formed from serine by the enzymes cystathionine β-synthase, and
cystathionine γ-lyase. In spheroids, these cysteine synthesis enzymes were highly active
because the cysteine pool contained relatively the same fraction of labeled molecules as the
serine pool (Figure 5A). The metabolic precursor 3-phosphoglycerate was most likely
labeled on the third carbon following feeding with 1-13C glucose. Synthesis pathways a and
b would have transferred label to the side-chain carbons (carbon-3) of both serine and
cysteine. The synthesis of glycine by serine hydroxymethyl-transferase (pathway c) removes
the side chain carbon (carbon-3) from serine. Lack of glycine labeling could have been
caused by removal of labeled carbon or inactivity of pathway c.
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First carbon (M+1) labeling of alanine (P<0.01) indicates that alanine aminotransferase
(pathways d) is active. The M+1 labeling on alanine (0.403; 99% CI, 0.370 to 0.436; Figure
5A) was significantly (P>0.01) less than 50%, indicating that pyruvate labeling was diluted.
Because alanine is derived directly from pyruvate, the labeling pattern of alanine equals the
labeling of pyruvate. Without dilution the extent of pyruvate M+1 labeling would have been
expected to be 50%, because two pyruvate molecules are synthesized from each glucose
molecule. Two mechanisms could contribute to dilution of pyruvate labeling: 1) the pentose
phosphate pathway (pathway e) and 2) protein turnover. If the pentose phosphate pathway
was active, pyruvate labeling would have been diminished, because glucose 6-phosphate
dehydrogenase removes the labeled first carbon from glucose. Protein turnover would have
reduced pyruvate labeling by producing unlabeled amino acids. The breakdown of cysteine,
serine, glycine, alanine, threonine and tryptophan would all dilute pyruvate labeling. The M
+1 labeling on alanine indicates that at least one of these two pathways is active; however,
GC-MS data alone cannot isolate their individual activities. Based on previous NMR studies
it is probable both pathways are active1–2.
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Four of the detected non-essential amino acids are synthesized from TCA cycle metabolites:
aspartate, glutamate, glutamine, and proline (Figure 5B). Aspartate is synthesized from
oxaloacetate (OAA), and glutamate, glutamine, and proline are synthesized from αketoglutarate (Figure 6). Single (M+1) labeling was observed for aspartate (P<0.01),
glutamate (P<0.01) and proline (P<0.01) indicating that aspartate aminotransferase (pathway
f), aminotransferase (pathway g), and pyroline-2-carboxylate reductase (pathway h) were all
active. The lack of any labeling on glutamine (Figure 5B) indicates that glutamine
synthetase was inactive and not producing glutamine (pathway i). Because glutamine was
consumed (Figure 2), glutaminase (pathway j) was active in the reverse direction producing
glutamate from glutamine.
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Two of the detected amino acids, glutamate and proline, had significant (P<0.01) double
labeling (M+2). The most predominant source of double labeling in primary metabolism is
the action of citrate synthase (pathway k), which joins one four-carbon molecule of OAA
with one two-carbon molecule of acetyl-CoA. If both molecules are labeled, a doubly
labeled molecule of citrate is produced. The double labeling of glutamate and proline
indicates that 1) the TCA cycle is active in both small and large spheroids, 2) labeled OAA
was produced, and 3) much of the cell’s glutamate and proline are produced from a well
mixed α-ketoglutarate pool.
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The extent of double labeling on glutamate and proline suggests the rate of diluting
pathways into TCA-cycle intermediates is proportional to the rate of the TCA cycle. These
diluting fluxes include the degradation of unlabeled proteins, the catabolism of many amino
acids, and the breakdown of unlabeled fatty acids into acetyl-coA1–2, 26–27. If these diluting
fluxes were slower than the TCA cycle, then the fraction of doubly labeled metabolites
would be greater and there would be more higher order, multiply labeled (M+3 and M+4)
amino acids. Conversely, if the diluting fluxes were considerably faster, labeled OAA would
not be produced and no doubly labeled species would have been observed.
Gluconeogenesis, Malic Enzyme, and Glutaminolysis
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The absence of significant double labeling (M+2) on serine, cysteine, and alanine (Figure
5A) indicates that the pathways that connect TCA-cycle metabolites with glycolysis
metabolites were minimally active. The primary connecting pathways are
phosphoenolpyruvate carboxykinase (PEPCK) and malic enzyme (pathways l and m,
respectively). PEPCK, the initial enzyme of gluconeogenesis, was completely inactive
because serine, cysteine, and hence, the combined cytosolic 3-phosphoglycerate (3GP) and
phosphoenolpyruvate (PEP) pool did not contain any doubly labeled species. It is not
surprising that gluconeogenesis is inactive in cultures adequately supplied with glucose.
The absence of significant double labeling on alanine and pyruvate suggests that extramitochondrial malic enzyme (pathway m) was minimally active. Reduced activity of malic
enzyme suggests that consumed glutamine carbons were used predominantly for
biosynthesis. Glutamine consumption is an anapleurotic reaction that increases the pool of
TCA-cycle metabolites28. At metabolic steady state, anapleurotic reactions must be balanced
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by carbon flux out of the mitochondria. Complete oxidation of these carbons to CO2
requires the activity of PEPCK or malic enzyme to produce pyruvate. When these pathways
are inactive, glutamine carbons cannot be converted into pyruvate and glutamine
consumption must increase flux to cytosolic pools of citrate and aspartate, which are in turn
used to synthesize nucleosides, proteins, lipids, and cholesterol1, 28. Although this evidence
for glutamine being utilized primarily for biosynthesis is indirect, this phenomenon has been
observed previously in multiple cell lines1–2. This observation does not indicate that rastransformed fibroblasts cannot use glutamine for energy production, only that they are not
doing so under these conditions. Similar rates of glutamine consumption in small and large
spheroids (Figure 2D) and the absence of any labeling differences (Figure 5) suggests that
rates of biosynthesis are similar in both spheroid sizes.

Conclusions
Author Manuscript

Using gas chromatography – mass spectrometry we have determined whether 13 critical
metabolic pathways are active or inactive (Table 1). GC-MS is a powerful technique because
it requires considerably less cell material (100-fold less spheroids) to obtain measurable
results compared to alternate techniques, i.e. NMR. The most significant results were that 1)
cells actively synthesize serine, cysteine, alanine, aspartate, glutamate, and proline; 2) cells
do not synthesize glutamine; 3) glutaminolysis was active; and 4) malic enzyme and
gluconeogenesis were inactive. The activities of these pathways suggest that cancer cells
consume glutamine for biosynthesis and not to provide cellular energy. Determining which
pathways are active under physiological meaningful conditions is useful because it indicates
how cells direct carbon flow, and because it may lead to the discovery of molecular targets
that could act as anti-cancer therapeutics.
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Figure 1.

A) Fragmentation pattern of glutamate derivatized with tert-butyldimethylsilyl (tBDMS).
Curved dashed lines indicate two prevalent fragmentation sites that produce the R-tButyl and
R-COOtBDMS fragments. B) Mass distribution of the R-tbutyl (M=432) fragment of
derivatized glutamate due to natural abundance.
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Figure 2.

A) Microenvironment regions present in small and large spheroids. Large spheroids had
54% more cells and a higher ratio of quiescent to proliferating cells. The images are drawn
to scale. B,C) Concentration profiles of four extracellular metabolites for (B) small and (C)
large spheroids. Glucose and glutamine were consumed, and glutamate and lactate were
produced. Cytoplasmic amino acids were extracted immediately after the final time point. D)
Absolute values of extracellular fluxes.
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Figure 3.

A) Representative chromatogram of total ion abundance over time showing elution of amino
acid metabolites. Each amino acid was identified by its mass spectrum and confirmed by its
elution order. B) Glutamate mass spectrum showing characteristic fragmentation peaks at
432, 330, and 272. C,D) Expansion of the mass distributions for the glutamate (C) 432, Rtbutyl; and (D) 330, R-COOtBDMS fragments. E) Analysis of the glutamate 432 fragment.
Each higher mass species is composed of labeled glutamate and natural abundance isotopes.
Degree of labeling was determined by numerical optimization.
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Figure 4.

Isotopomer distribution for essential amino acids. Ordinate labels indicate mass number.

Author Manuscript
Author Manuscript
Biotechnol Prog. Author manuscript; available in PMC 2016 August 03.

Hunnewell and Forbes

Page 15

Author Manuscript
Author Manuscript
Figure 5.
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Isotopomer distribution for non-essential amino acids produced from (A) glycolysis and (B)
TCA-cycle metabolites. Ordinate labels indicate mass number. Singly labeled species (1, M
+1) were observed for alanine, serine, cysteine, aspartate, glutamate and proline; and doubly
labeled species (2, M+2) were observed for glutamate and proline (†, P<0.05; *, P<0.01;
n=4).
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Figure 6.

Metabolic pathway model, which contains glycolysis, the TCA cycle and some biosynthetic
pathways. Labeled pathways are: a) serine synthesis, b) cysteine synthesis, c) glycine
synthesis, d) alanine synthesis, e) the pentose phosphate pathway, f) aspartate synthesis, g)
glutamate synthesis, h) proline synthesis, i) glutamine synthesis, j) glutamine degradation, k)
citrate synthase, l) phosphoenolpyruvate carboxykinase, and m) malic enzyme. Active and
inactive pathways are indicated with arrows and X’s, respectively.
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Table 1
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Active and Inactive Intracellular Pathways

Author Manuscript

Pathway

Primary enzyme(s)

Activity

a) Serine synthesis

3-phosphoglycerate dehydrogenase,
Phosphoserine phosphatase

Active

b) Cysteine synthesis

Cystathionine β-synthase,
Cystathionine γ-lyase

Active

c) Glycine synthesis

Serine hydroxymethyl-transferase

N.D.

d) Alanine synthesis

Alanine aminotransferase

Active

e) Pentose phosphate pathway
or Protein turnover

Glucose 6-phosphate dehydrogenase
Numerous proteases

Active

f) Aspartate synthesis

Aspartate aminotransferase

Active

g) Glutamate synthesis

Glutamate dehydrogenase

Active

h) Proline synthesis

Pyroline-2-carboxylate reductase

Active

i) Glutamine synthesis

Glutamine synthetase

Inactive

j) Glutamine degradation

Glutaminase

Active

k) TCA cycle

Citrate synthase

Active

l) Gluconeogenesis

Phosphoenolpyruvate carboxykinase

Inactive

m) TCA-cycle intermediate
catabolism

Malic enzyme

Inactive

N.D. – not determined
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